129 related articles for article (PubMed ID: 37768116)
1. [he importance of mTOR hyperactivity and RICTOR amplification, and the associated targeted therapy possibilities in malignant tumours].
Szalai F; Krencz I; Moldvai D; Petővári G; Dankó T; Nagy N; Papp G; Pápay J; Sebestyén A; Sztankovics D
Magy Onkol; 2023 Sep; 67(3):165-180. PubMed ID: 37768116
[TBL] [Abstract][Full Text] [Related]
2. mTOR hyperactivity and
Sztankovics D; Moldvai D; Petővári G; Dankó T; Szalai F; Miyaura R; Varga V; Nagy N; Papp G; Pápay J; Krencz I; Sebestyén A
Pathol Oncol Res; 2024; 30():1611643. PubMed ID: 38515456
[TBL] [Abstract][Full Text] [Related]
3. RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma.
Lu Z; Shi X; Gong F; Li S; Wang Y; Ren Y; Zhang M; Yu B; Li Y; Zhao W; Zhang J; Hou G
Acta Pharm Sin B; 2020 Jun; 10(6):1004-1019. PubMed ID: 32642408
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
5. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin and mTORC2 inhibition synergistically reduce contraction-stimulated muscle protein synthesis.
Ogasawara R; Knudsen JR; Li J; Ato S; Jensen TE
J Physiol; 2020 Dec; 598(23):5453-5466. PubMed ID: 32893874
[TBL] [Abstract][Full Text] [Related]
7. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA
Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655
[TBL] [Abstract][Full Text] [Related]
8. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
Julien LA; Carriere A; Moreau J; Roux PP
Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
[TBL] [Abstract][Full Text] [Related]
9. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
10. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
Zou Z; Chen J; Yang J; Bai X
Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
[TBL] [Abstract][Full Text] [Related]
11.
Kim LC; Rhee CH; Chen J
Mol Cancer Res; 2020 Nov; 18(11):1675-1684. PubMed ID: 32801163
[TBL] [Abstract][Full Text] [Related]
12. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
13. Identification of rictor as a novel substrate of Polo-like kinase 1.
Shao T; Liu X
Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006
[TBL] [Abstract][Full Text] [Related]
14. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.
Rosner M; Hengstschläger M
Hum Mol Genet; 2008 Oct; 17(19):2934-48. PubMed ID: 18614546
[TBL] [Abstract][Full Text] [Related]
16. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
17. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
18. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.
Gulhati P; Bowen KA; Liu J; Stevens PD; Rychahou PG; Chen M; Lee EY; Weiss HL; O'Connor KL; Gao T; Evers BM
Cancer Res; 2011 May; 71(9):3246-56. PubMed ID: 21430067
[TBL] [Abstract][Full Text] [Related]
19. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
Montero JC; Chen X; Ocaña A; Pandiella A
Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
[TBL] [Abstract][Full Text] [Related]
20. Alcohol-induced modulation of rictor and mTORC2 activity in C2C12 myoblasts.
Hong-Brown LQ; Brown CR; Navaratnarajah M; Huber DS; Lang CH
Alcohol Clin Exp Res; 2011 Aug; 35(8):1445-53. PubMed ID: 21438886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
